Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IV trial of concomitant sIPV, DTaP, and MMR booster immunization at 18 months
ChiCTR2000040389Phase 4Not yet recruiting
- Sponsor
- Jiangsu Provincial Center for Disease Control and Prevention
- Start
- Dec 2020
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Sabin Inactivated Poliovirus Vaccine (Vero Cell), diphtheria, tetanus, and acellular pertussis vaccine and M-M-R II in poliomyelitis, pertussis, diphtheria and 4 more (4 arms), sponsored by Jiangsu Provincial Center for Disease Control and Prevention. Primary endpoints: Antibody positive rate (sIPV), Seroconversion rate (sIPV) and 7 more. Planned start Dec 2020; status: not yet recruiting.
02
Drugs
Sabin Inactivated Poliovirus Vaccine (Vero Cell)diphtheria, tetanus, and acellular pertussis vaccineM-M-R II
03
Conditions
poliomyelitispertussisdiphtheriaTetanusmeasles
Beyond the preview
Go deeper on ChiCTR2000040389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040389.